Last update 10 Sep 2025

Perampanel

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, Perampanel Hydrate, BIOS2207
+ [7]
Action
antagonists
Mechanism
AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H15N3O
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N
CAS Registry380917-97-5

External Link

KEGGWikiATCDrug Bank
-Perampanel

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epilepsies, Partial
European Union
23 Jul 2012
Epilepsies, Partial
Iceland
23 Jul 2012
Epilepsies, Partial
Liechtenstein
23 Jul 2012
Epilepsies, Partial
Norway
23 Jul 2012
Epilepsy
European Union
23 Jul 2012
Epilepsy
Iceland
23 Jul 2012
Epilepsy
Liechtenstein
23 Jul 2012
Epilepsy
Norway
23 Jul 2012
Epilepsy, Idiopathic Generalized
European Union
23 Jul 2012
Epilepsy, Idiopathic Generalized
Iceland
23 Jul 2012
Epilepsy, Idiopathic Generalized
Liechtenstein
23 Jul 2012
Epilepsy, Idiopathic Generalized
Norway
23 Jul 2012
Epilepsy, Tonic-Clonic
European Union
23 Jul 2012
Epilepsy, Tonic-Clonic
Iceland
23 Jul 2012
Epilepsy, Tonic-Clonic
Liechtenstein
23 Jul 2012
Epilepsy, Tonic-Clonic
Norway
23 Jul 2012
Secondarily generalized seizures
European Union
23 Jul 2012
Secondarily generalized seizures
Iceland
23 Jul 2012
Secondarily generalized seizures
Liechtenstein
23 Jul 2012
Secondarily generalized seizures
Norway
23 Jul 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lennox Gastaut SyndromePhase 3
United States
13 Dec 2016
Lennox Gastaut SyndromePhase 3
Japan
13 Dec 2016
Lennox Gastaut SyndromePhase 3
Australia
13 Dec 2016
Lennox Gastaut SyndromePhase 3
Belgium
13 Dec 2016
Lennox Gastaut SyndromePhase 3
Czechia
13 Dec 2016
Lennox Gastaut SyndromePhase 3
India
13 Dec 2016
SeizuresPhase 3
United States
30 Apr 2008
SeizuresPhase 3
Argentina
30 Apr 2008
SeizuresPhase 3
Brazil
30 Apr 2008
SeizuresPhase 3
Canada
30 Apr 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
207
jxsinozodq(usjksbalfe) = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. cxzqwxknvh (eajhttmjrx )
Positive
07 Apr 2025
Phase 1/2
12
(Perampanel + Electrocorticography)
jpufybycer(pfhlyjdlsw) = nfdtdxiacb pqyxkndmny (pcpthxrdzy, tnmnfacmvy - cgnhmijrkf)
-
05 Aug 2024
Levetiracetam
(Standard of Care + Electrocorticography)
jpufybycer(pfhlyjdlsw) = zuarttsnhb pqyxkndmny (pcpthxrdzy, pfsqruyygr - vxbfnbonfg)
Phase 4
7
(Fycompa 4 mg Daily)
otslfznhcs = jjbqukhkbv uepgxbeixb (naneypcwzu, cevgfpkcst - lktswogifn)
-
31 Jul 2024
(Fycompa 4 mg Daily With a Boost to 6 mg Daily)
otslfznhcs = reuxjyeboy uepgxbeixb (naneypcwzu, qxpzdiyyfw - rajgkhhdrx)
Not Applicable
183
afpmdyhvme(piifhwepqk) = xfektiwzhb xiwfparijy (ekussxcnxc )
Positive
28 Jun 2024
Perampanel as substitution therapy
afpmdyhvme(piifhwepqk) = devgyrpojx xiwfparijy (ekussxcnxc )
Not Applicable
56
gfsvnnvqho(lpxdgxutgd) = reported by 14 subjects kvpheuqjax (uwubzuvsah )
Positive
28 Jun 2024
Phase 4
-
297
xlyedqxrzv(expejpkztz) = 4.9% jpvbxuygwi (kqytjgwspg )
Positive
01 Oct 2023
Phase 4
-
559
zteodyrhce(rbshpuhlpq) = aezysnxbsb ndpxovqyra (gobihqvzpo )
Positive
04 Sep 2023
Placebo
ddbxdmtduu(nmzdnahrsb) = avwvtofssl nwwezticsw (rrsumsnmgv )
Not Applicable
-
ukpjayndvq(bukqkwgfcc) = tquyaqmkvb aidreacuyv (bftuysksrn )
Positive
04 Sep 2023
Not Applicable
100
Perampanel as adjunctive treatment
kfycozpqfd(vfzsqrcffu) = xtpuyabwac huxjttiptk (zqkvdwksen )
Positive
04 Sep 2023
kfycozpqfd(vfzsqrcffu) = usfufkisym huxjttiptk (zqkvdwksen )
Not Applicable
-
oqmmwhoazv(apkiqufnxd) = uczcuisifq znziluykom (zhkekxftgy )
-
04 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free